Clinical Trial Update: Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating infliximab with intravenous immunoglobulin for steroid-refractory pneumonitis in patients with hematologic or solid malignancies; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Malignant Solid Neoplasm
• Pneumonitis

Drugs mentioned

• Infliximab (infliximab)
• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2024-03-26